Exploration of the Combination of PLK1 Inhibition with Immunotherapy in Cancer Treatment

Table 1

The 33 TCGA cancer types analyzed.

Cancer type	Full name	# Cancer samples
ACC	adrenocortical carcinoma	79
BLCA	bladder urothelial carcinoma	408
BRCA	breast invasive carcinoma	1100
CESC	cervical squamous-cell carcinoma and endocervical adeno-carcinoma	306
CHOL	cholangiocarcinoma	36
COAD	colon adenocarcinoma	287
DLBC	lymphoid neoplasm diffuse large B-cell lymphoma	48
ESCA	esophageal carcinoma	185
GBM	glioblastoma multiforme	166
HNSC	head and neck squamous cell carcinoma	522
KICH	kidney chromophobe	66
KIRC	kidney renal clear cell carcinoma	534
KIRP	kidney renal papillary cell carcinoma	291
LAML	acute myeloid leukemia	173
LGG	brain lower-grade glioma	530
LIHC	liver hepatocellular carcinoma	373
LUAD	lung adenocarcinoma	517
LUSC	lung squamous cell carcinoma	501
MESO	mesothelioma	87
OV	ovarian serous cystadenocarcinoma	307
PAAD	pancreatic adeno-carcinoma	179
PCPG	pheochromocytoma and paraganglioma	184
PRAD	prostate adenocarcinoma	498
READ	rectum adenocarcinoma	95
SARC	sarcoma	263
SKCM	skin cutaneous melanoma	472
STAD	stomach adenocarcinoma	415
TGCT	testicular germ-cell tumors	156
THCA	thyroid carcinoma	509
THYM	thymoma	120
UCEC	uterine corpus endometrial carcinoma	370
UCS	uterine carcinosarcoma	57
UVM	uveal melanoma	80